BORDEAUX, France–(BUSINESS WIRE)–Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – ticker: AELIS), a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases, today announces that its half-year financial report has been made available to the public and filled with the French Financial Markets Authority (Autorité des marchés financiers). It can be consulted on the Company’s website, www.aelisfarma.com, in the section Investors/Documentation/Reports. *** Abo
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://mmpconnect.com/aelis-farma-availability-of-the-2023-half-year-financial-report/?utm_source=rss&utm_medium=rss&utm_campaign=aelis-farma-availability-of-the-2023-half-year-financial-report
